Analyst Target Signals
Showing 197 signals. Updated 2026-04-28. Highlighting VSTM.
Price$9.89
Signal$8.82|+12.1%|+046022-01-01 08:00
TargetsPT $26.00 | Cons $24.67
UpsideImp +194.8% | Cons +179.7%
Price$10.18
Signal$5.98|+70.3%|+046022-01-01 08:00
TargetsPT $15.00 | Cons $13.50
UpsideImp +150.8% | Cons +125.8%
Price$23.68
Signal$16.23|+45.9%|2026-01-06 20:49:28
Headline: Alumis price target raised to $50 from $25 at Oppenheimer
TargetsPT $50.00 | Cons $34.33
UpsideImp +208.1% | Cons +111.5%
Price$6.00
Signal$7.00|-14.2%|2026-01-08 17:46:51
Headline: Ardelyx price target raised to $19 from $16 at Raymond James
TargetsPT $19.00 | Cons $15.60
UpsideImp +171.6% | Cons +123.0%
Price$12.79
Signal$10.77|+18.8%|2026-01-08 14:44:28
Headline: Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright
TargetsPT $27.00 | Cons $31.00
UpsideImp +150.7% | Cons +187.8%
Price$1.13
Signal$0.99|+13.2%|2026-01-14 14:28:00
Headline: DA Davidson Reiterates Buy Rating on BRC Inc. (BRCC)
TargetsPT $2.50 | Cons $2.50
UpsideImp +151.6% | Cons +151.6%
Price$23.14
Signal$23.53|-1.6%|2026-01-20 16:24:40
Headline: FDA draft guidance favorable for Legend Biotech, says RBC Capital
TargetsPT $66.00 | Cons $62.17
UpsideImp +180.5% | Cons +164.3%
Price$4.28
Signal$3.64|+17.4%|2026-01-20 11:50:04
Headline: Atai Beckley initiated with a Buy at Guggenheim
TargetsPT $11.00 | Cons $12.33
UpsideImp +202.2% | Cons +238.7%
Price$4.95
Signal$2.10|+135.8%|2026-01-20 10:44:01
Headline: Opus Genetics initiated with a Buy at BTIG
TargetsPT $7.00 | Cons $7.00
UpsideImp +233.3% | Cons +233.3%
Price$8.79
Signal$7.59|+15.7%|2026-01-22 21:08:58
Headline: Arcturus Therapeutics initiated with a Buy at Roth Capital
TargetsPT $20.00 | Cons $37.00
UpsideImp +163.5% | Cons +387.5%
Price$19.29
Signal$16.73|+15.3%|2026-01-23 19:24:14
Headline: GH Research price target raised to $40 from $33 at RBC Capital
TargetsPT $40.00 | Cons $35.17
UpsideImp +139.1% | Cons +110.2%
Price$7.09
Signal$3.96|+79.1%|2026-01-23 11:24:34
Headline: Relmada Therapeutics assumed at Outperform from Market Perform at Leerink
TargetsPT $8.00 | Cons $8.50
UpsideImp +102.0% | Cons +114.6%
Price$83.91
Signal$36.35|+130.8%|2026-01-26 13:56:00
Headline: Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked…
TargetsPT $105.00 | Cons $119.00
UpsideImp +188.9% | Cons +227.4%
Price$12.70
Signal$11.69|+8.6%|2026-01-28 23:12:24
Headline: Korro Bio upgraded to Overweight from Neutral at Piper Sandler
TargetsPT $30.00 | Cons $19.67
UpsideImp +156.6% | Cons +68.3%
Price$84.55
Signal$53.23|+58.8%|2026-01-29 13:06:01
Headline: Dianthus price target raised to $125 from $62 at Oppenheimer
TargetsPT $125.00 | Cons $80.20
UpsideImp +134.8% | Cons +50.7%
Price$4.07
Signal$4.26|-4.5%|2026-01-30 11:08:17
Headline: Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright
TargetsPT $12.00 | Cons $11.00
UpsideImp +181.7% | Cons +158.2%
Price$6.86
Signal$10.27|-33.3%|2026-01-30 09:58:00
Headline: enGene initiated with a Buy at Jefferies
TargetsPT $28.00 | Cons $24.00
UpsideImp +172.6% | Cons +133.7%
Price$12.79
Signal$11.96|+6.9%|2026-02-02 00:19:56
Headline: Cullinan Therapeutics initiated with a Buy at Guggenheim
TargetsPT $30.00 | Cons $30.83
UpsideImp +150.8% | Cons +157.8%
Price$446.46
Signal$387.34|+15.3%|2026-02-04 23:07:34
Headline: AppLovin derating creates potential opportunity, says Morgan Stanley
TargetsPT $800.00 | Cons $755.85
UpsideImp +106.5% | Cons +95.1%
Price$1.87
Signal$6.42|-71.0%|2026-02-04 11:36:12
Headline: Compass Therapeutics price target raised to $13 from $10 at Canaccord
TargetsPT $13.00 | Cons $10.50
UpsideImp +102.5% | Cons +63.6%
Price$16.82
Signal$14.73|+14.2%|2026-02-09 09:54:41
Headline: Cipher Mining initiated with an Overweight at Morgan Stanley
TargetsPT $38.00 | Cons $26.31
UpsideImp +158.0% | Cons +78.6%
Price$20.40
Signal$14.29|+42.7%|2026-02-09 09:53:10
Headline: TeraWulf initiated with an Overweight at Morgan Stanley
TargetsPT $37.00 | Cons $22.50
UpsideImp +158.9% | Cons +57.5%
Price$83.91
Signal$52.62|+59.5%|2026-02-10 14:16:02
Headline: Nektar price target raised to $165 from $135 at H.C. Wainwright
TargetsPT $165.00 | Cons $131.40
UpsideImp +213.6% | Cons +149.7%
Price$82.13
Signal$75.92|+8.2%|2026-02-11 14:29:00
Headline: Bernstein Reiterates Outperform Rating on Robinhood Markets (HOOD)
TargetsPT $160.00 | Cons $137.71
UpsideImp +110.7% | Cons +81.4%
Price$446.46
Signal$372.29|+19.9%|2026-02-12 14:44:21
Headline: AppLovin price target raised to $775 from $750 at Scotiabank
TargetsPT $775.00 | Cons $690.93
UpsideImp +108.2% | Cons +85.6%
Price$4.25
Signal$5.33|-20.3%|2026-02-17 13:48:15
Headline: Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
TargetsPT $12.00 | Cons $10.50
UpsideImp +125.1% | Cons +97.0%
Price$10.18
Signal$7.47|+36.3%|2026-02-17 11:36:06
Headline: Vir Biotechnology price target raised to $26 from $24 at Barclays
TargetsPT $26.00 | Cons $20.50
UpsideImp +248.1% | Cons +174.4%
Price$5.42
Signal$5.71|-5.1%|2026-02-19 12:18:20
Headline: Verastem price target raised to $18 from $15 at Mizuho
TargetsPT $18.00 | Cons $15.00
UpsideImp +215.2% | Cons +162.7%
Price$134.10
Signal$99.29|+35.1%|2026-02-23 13:21:05
Headline: Nebius price target raised to $232 from $211 at Northland
TargetsPT $232.00 | Cons $156.33
UpsideImp +133.7% | Cons +57.4%
Price$10.18
Signal$7.43|+37.1%|2026-02-24 11:49:58
Headline: Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley
TargetsPT $24.00 | Cons $20.67
UpsideImp +223.0% | Cons +178.2%
Price$65.36
Signal$82.62|-20.9%|2026-02-24 18:10:04
Headline: Jefferies trims Planet Fitness price target, sees 'strong buying opportunity'
TargetsPT $175.00 | Cons $134.00
UpsideImp +111.8% | Cons +62.2%
Price$10.18
Signal$9.33|+9.2%|2026-02-26 18:07:00
Headline: Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners
TargetsPT $20.00 | Cons $20.57
UpsideImp +114.5% | Cons +120.6%
Price$14.40
Signal$13.41|+7.3%|2026-03-03 14:49:00
Headline: Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results
TargetsPT $30.00 | Cons $22.33
UpsideImp +123.7% | Cons +66.5%
Price$23.59
Signal$23.82|-1.0%|2026-03-03 10:48:00
Headline: DraftKings Inc. (DKNG) PT Raised to $50 at BMO Capital, Top Pick
TargetsPT $50.00 | Cons $37.61
UpsideImp +109.9% | Cons +57.9%
Price$8.79
Signal$7.42|+18.4%|2026-03-04 12:52:00
Headline: '2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler
TargetsPT $25.00 | Cons $22.50
UpsideImp +236.9% | Cons +203.2%
Price$10.18
Signal$9.13|+11.6%|2026-03-04 11:41:00
Headline: Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright
TargetsPT $20.00 | Cons $21.29
UpsideImp +119.1% | Cons +133.2%
Price$13.19
Signal$13.01|+1.3%|2026-03-05 17:55:00
Headline: Jefferies Reiterates Buy Rating on Sable Offshore Corp. (SOC) amid DOJ formal opinion
TargetsPT $28.00 | Cons $27.00
UpsideImp +115.2% | Cons +107.5%
Price$5.42
Signal$6.18|-12.3%|2026-03-05 15:06:00
Headline: Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026"
TargetsPT $19.00 | Cons $16.00
UpsideImp +207.4% | Cons +158.9%
Price$16.42
Signal$16.52|-0.6%|2026-03-05 14:23:00
Headline: Rosenblatt Reiterates Buy Rating on Rigetti Computing Inc. (RGTI), raises rev estimate
TargetsPT $40.00 | Cons $38.33
UpsideImp +142.2% | Cons +132.1%
Price$4.28
Signal$3.39|+26.1%|2026-03-06 20:37:00
Headline: Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Pha…
TargetsPT $10.00 | Cons $11.75
UpsideImp +195.0% | Cons +246.6%
Price$26.84
Signal$14.07|+90.8%|2026-03-06 17:15:00
Headline: Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101"
TargetsPT $40.00 | Cons $31.00
UpsideImp +184.4% | Cons +120.4%
Price$23.67
Signal$23.67|0.0%|2026-03-06 12:32:00
Headline: Badger Infrastructure Solutions Ltd (BDGI:CN) (BADFF) PT Lowered at BMO Capital
TargetsPT $80.00 | Cons $43.52
UpsideImp +238.0% | Cons +83.9%
Price$19.29
Signal$15.34|+25.8%|2026-03-06 12:04:00
Headline: GH Research PLC (GHRS) PT Raised to $32 at Needham
TargetsPT $32.00 | Cons $35.67
UpsideImp +108.7% | Cons +132.6%
Price$3.06
Signal$2.32|+31.7%|2026-03-09 20:22:00
Headline: Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings
TargetsPT $6.00 | Cons $6.00
UpsideImp +158.6% | Cons +158.6%
Price$18.02
Signal$17.69|+1.9%|2026-03-09 11:11:00
Headline: Wells Fargo Upgrades uniQure BV (QURE) to Overweight
TargetsPT $60.00 | Cons $41.80
UpsideImp +239.3% | Cons +136.4%
Price$5.58
Signal$9.51|-41.4%|2026-03-09 14:57:00
Headline: Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS)
TargetsPT $23.00 | Cons $21.00
UpsideImp +141.9% | Cons +120.8%
Price$6.86
Signal$7.79|-12.0%|2026-03-09 14:16:00
Headline: Raymond James Reiterates Strong Buy Rating on Engene Holdings Inc. (ENGN) following Q1 results
TargetsPT $27.00 | Cons $24.60
UpsideImp +246.6% | Cons +215.8%
Price$23.67
Signal$23.67|0.0%|2026-03-09 12:40:00
Headline: AltaGas Ltd. (ALA:CN) (ATGFF) PT Raised to Cdn$49 at BMO Capital
TargetsPT $49.00 | Cons $39.09
UpsideImp +107.0% | Cons +65.1%
Price$9.31
Signal$7.33|+27.0%|2026-03-10 20:06:00
Headline: Raymond James Starts Climb Bio (CLYM) at Strong Buy
TargetsPT $25.00 | Cons $18.00
UpsideImp +241.1% | Cons +145.6%
Price$100.98
Signal$83.89|+20.4%|2026-03-10 18:28:00
Headline: Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes
TargetsPT $155.00 | Cons $138.71
UpsideImp +84.8% | Cons +65.3%
Price$5.62
Signal$5.99|-6.2%|2026-03-10 16:20:00
Headline: H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key cli…
TargetsPT $13.00 | Cons $13.00
UpsideImp +117.0% | Cons +117.0%
Price$23.14
Signal$19.56|+18.3%|2026-03-10 16:10:00
Headline: Truist Securities Reiterates Buy Rating on Legend Biotech Corp. (LEGN): "infer from comments that Ra…
TargetsPT $70.00 | Cons $58.60
UpsideImp +257.9% | Cons +199.6%
Price$6.90
Signal$8.11|-14.9%|2026-03-10 13:16:00
Headline: Craig-Hallum Reiterates Buy Rating on Jumia Technologies (JMIA): "we expect quarters to start to sta…
TargetsPT $18.00 | Cons $17.33
UpsideImp +122.1% | Cons +113.8%
Price$4.08
Signal$3.14|+30.0%|2026-03-10 13:08:00
Headline: DA Davidson Reiterates Buy Rating on Repay (RPAY) Following Q4 Results
TargetsPT $9.00 | Cons $6.83
UpsideImp +187.1% | Cons +117.9%
Price$19.29
Signal$15.81|+22.0%|2026-03-10 10:40:00
Headline: GH Research PLC (GHRS) PT Raised to $34 at Guggenheim
TargetsPT $34.00 | Cons $36.50
UpsideImp +115.1% | Cons +130.9%
Price$9.89
Signal$11.03|-10.3%|2026-03-10 10:40:00
Headline: Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim
TargetsPT $23.00 | Cons $24.25
UpsideImp +108.5% | Cons +119.9%
Price$7.89
Signal$9.28|-15.0%|2026-03-10 10:22:00
Headline: ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners
TargetsPT $26.00 | Cons $29.33
UpsideImp +180.2% | Cons +216.1%
Price$25.79
Signal$27.23|-5.3%|2026-03-10 10:12:00
Headline: H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TargetsPT $56.00 | Cons $54.00
UpsideImp +105.7% | Cons +98.3%
Price$6.00
Signal$5.66|+6.1%|2026-03-12 19:10:00
Headline: Leerink Partners Reiterates Outperform Rating on Ardelyx, Inc (ARDX) following conference
TargetsPT $17.00 | Cons $17.00
UpsideImp +200.4% | Cons +200.4%
Price$33.09
Signal$35.47|-6.7%|2026-03-12 16:48:00
Headline: Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this yea…
TargetsPT $101.00 | Cons $103.00
UpsideImp +184.7% | Cons +190.4%
Price$1.67
Signal$1.70|-1.8%|2026-03-12 16:26:00
Headline: H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX): "significant upside potenti…
TargetsPT $6.00 | Cons $6.00
UpsideImp +252.5% | Cons +252.5%
Price$16.48
Signal$15.58|+5.8%|2026-03-12 15:53:00
Headline: H.C. Wainwright Reiterates Buy Rating on Pharming Group (PHAR): "well positioned to drive value"
TargetsPT $37.00 | Cons $39.50
UpsideImp +137.5% | Cons +153.5%
Price$24.83
Signal$21.36|+16.2%|2026-03-12 14:39:00
Headline: Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clini…
TargetsPT $60.00 | Cons $49.90
UpsideImp +180.9% | Cons +133.6%
Price$0.69
Signal$0.95|-26.9%|2026-03-12 14:37:00
Headline: Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "remains on track t…
TargetsPT $2.00 | Cons $2.33
UpsideImp +110.5% | Cons +145.3%
Price$4.56
Signal$3.88|+17.5%|2026-03-12 14:07:00
Headline: LifeMD Inc (LFMD) PT Raised to $10 at Freedom Capital Markets
TargetsPT $10.00 | Cons $8.50
UpsideImp +157.7% | Cons +119.1%
Price$2.73
Signal$1.70|+60.3%|2026-03-12 13:46:00
Headline: Stifel Reiterates Buy Rating on Codexis, Inc. (CDXS): "remains an interesting small cap idea"
TargetsPT $5.00 | Cons $5.00
UpsideImp +194.1% | Cons +194.1%
Price$3.33
Signal$3.36|-1.0%|2026-03-13 17:05:00
Headline: Morgan Stanley Reiterates Overweight Rating on Sana Biotechnology (SANA) after "meaningful platform…
TargetsPT $12.00 | Cons $9.00
UpsideImp +257.1% | Cons +167.9%
Price$4.63
Signal$4.19|+10.5%|2026-03-13 14:15:00
Headline: Sono-Tek (SOTK) PT Raised to $8.50 at Oak Ridge Financial
TargetsPT $8.50 | Cons $8.50
UpsideImp +102.9% | Cons +102.9%
Price$1.70
Signal$1.45|+17.3%|2026-03-13 13:28:00
Headline: DA Davidson Reiterates Buy Rating on Open Lending (LPRO)
TargetsPT $4.00 | Cons $4.00
UpsideImp +176.8% | Cons +176.8%
Price$38.99
Signal$38.99|0.0%|2026-03-13 13:28:00
Headline: ServiceTitan (TTAN) PT Raised to $135 at TD Cowen
TargetsPT $135.00 | Cons $106.67
UpsideImp +246.2% | Cons +173.6%
Price$1.41
Signal$1.38|+1.8%|2026-03-13 13:15:00
Headline: Stifel Reiterates Buy Rating on Century Casinos (CNTY) following Q4 report
TargetsPT $3.00 | Cons $2.50
UpsideImp +117.4% | Cons +81.2%
Price$3.01
Signal$3.01|+0.2%|2026-03-13 13:05:00
Headline: Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial'
TargetsPT $7.00 | Cons $7.00
UpsideImp +132.9% | Cons +132.9%
Price$13.16
Signal$10.81|+21.7%|2026-03-13 11:59:00
Headline: Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim
TargetsPT $22.00 | Cons $16.33
UpsideImp +103.4% | Cons +51.0%
Price$12.70
Signal$11.50|+10.4%|2026-03-13 08:26:00
Headline: Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform
TargetsPT $23.00 | Cons $20.29
UpsideImp +100.0% | Cons +76.4%
Price$11.20
Signal$9.31|+20.3%|2026-03-13 10:30:00
Headline: Prothena (PRTA) Reiterated at Market Outperform by Citizens After Fireside Chat
TargetsPT $19.00 | Cons $24.83
UpsideImp +104.1% | Cons +166.7%
Price$8.36
Signal$9.45|-11.6%|2026-03-16 16:32:00
Headline: VNET Group Inc (VNET) PT Raised to $23.55 at Jefferies, 'Growth to Accelerate', 'Still our top pick'
TargetsPT $23.55 | Cons $23.55
UpsideImp +149.2% | Cons +149.2%
Price$2.41
Signal$2.86|-15.9%|2026-03-16 15:40:00
Headline: H.C. Wainwright Reiterates Buy Rating on NovaBridge Biosciences (NBP) following FDA meeting feedback
TargetsPT $9.00 | Cons $9.00
UpsideImp +214.7% | Cons +214.7%
Price$9.31
Signal$7.12|+30.7%|2026-03-17 20:06:00
Headline: Truist Securities Starts Climb Bio (CLYM) at Buy
TargetsPT $17.00 | Cons $17.67
UpsideImp +138.8% | Cons +148.2%
Price$4.07
Signal$5.09|-20.0%|2026-03-17 12:35:00
Headline: Truist Reiterates Buy Rating on Perspective Therapeutics Inc (CATX)
TargetsPT $12.00 | Cons $12.20
UpsideImp +135.8% | Cons +139.7%
Price$44.69
Signal$56.88|-21.4%|2026-03-17 12:29:00
Headline: Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital
TargetsPT $145.00 | Cons $116.71
UpsideImp +154.9% | Cons +105.2%
Price$4.73
Signal$5.13|-7.9%|2026-03-17 12:29:00
Headline: Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right…
TargetsPT $13.00 | Cons $11.00
UpsideImp +153.4% | Cons +114.4%
Price$4.18
Signal$4.61|-9.3%|2026-03-18 14:16:00
Headline: CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here'
TargetsPT $16.00 | Cons $11.60
UpsideImp +247.4% | Cons +151.9%
Price$75.32
Signal$81.11|-7.1%|2026-04-27 15:28:28
Headline: Oruka Therapeutics price target raised to $200 from $125 at Guggenheim
TargetsPT $200.00 | Cons $141.83
UpsideImp +146.6% | Cons +74.9%
Price$54.59
Signal$55.63|-1.9%|2026-04-27 12:05:05
Headline: Spruce Biosciences initiated with a Buy at Craig-Hallum
TargetsPT $140.00 | Cons $227.33
UpsideImp +151.7% | Cons +308.6%
Price$16.82
Signal$18.45|-8.9%|2026-04-27 11:59:06
Headline: Cipher Mining price target raised to $40.50 from $38 at Morgan Stanley
TargetsPT $40.50 | Cons $27.86
UpsideImp +119.5% | Cons +51.0%
Price$53.62
Signal$53.18|+0.8%|2026-04-27 10:16:47
Headline: BioMarin resumed with an Overweight at Morgan Stanley
TargetsPT $120.00 | Cons $89.64
UpsideImp +125.6% | Cons +68.6%
Price$44.69
Signal$45.49|-1.8%|2026-04-27 09:55:46
Headline: Structure Therapeutics initiated with a Buy at Canaccord
TargetsPT $101.00 | Cons $114.75
UpsideImp +122.0% | Cons +152.3%
Price$19.29
Signal$15.80|+22.0%|2026-01-05 14:59:00
Headline: Guggenheim Reiterates Buy Rating on GH Research PLC (GHRS) Post Mgmt Call
TargetsPT $29.00 | Cons $34.20
UpsideImp +83.5% | Cons +116.4%
Price$1.87
Signal$4.89|-61.9%|2026-01-06 15:11:00
Headline: Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX)
TargetsPT $9.00 | Cons $9.67
UpsideImp +84.0% | Cons +97.7%
Price$84.55
Signal$38.09|+122.0%|2026-01-08 12:54:20
Headline: Dianthus price target raised to $63 from $56 at Truist
TargetsPT $63.00 | Cons $69.00
UpsideImp +65.4% | Cons +81.1%
Price$10.58
Signal$12.14|-12.9%|2026-01-20 11:04:33
Headline: Ondas price target raised to $25 from $12 at H.C. Wainwright
TargetsPT $25.00 | Cons $16.43
UpsideImp +106.0% | Cons +35.4%
Price$4.18
Signal$5.39|-22.5%|2026-01-20 11:48:45
Headline: CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler
TargetsPT $10.00 | Cons $8.75
UpsideImp +85.5% | Cons +62.3%
Price$53.62
Signal$54.59|-1.8%|2026-01-20 10:05:41
Headline: BioMarin upgraded to Buy from Hold at Canaccord
TargetsPT $98.00 | Cons $82.92
UpsideImp +79.5% | Cons +51.9%
Price$13.16
Signal$7.43|+77.1%|2026-01-26 11:22:55
Headline: Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer
TargetsPT $14.00 | Cons $13.50
UpsideImp +88.4% | Cons +81.7%
Price$30.29
Signal$36.07|-16.0%|2026-01-27 21:26:51
Headline: MBX Biosciences initiated with an Overweight at Barclays
TargetsPT $66.00 | Cons $53.33
UpsideImp +83.0% | Cons +47.9%
Price$12.70
Signal$10.74|+18.2%|2026-01-27 21:10:15
Headline: Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald
TargetsPT $21.00 | Cons $21.50
UpsideImp +95.5% | Cons +100.2%
Price$6.00
Signal$7.80|-23.0%|2026-01-27 11:23:17
Headline: Ardelyx price target raised to $15 from $8 at Jefferies
TargetsPT $15.00 | Cons $15.50
UpsideImp +92.3% | Cons +98.7%
Price$4.18
Signal$6.07|-31.2%|2026-02-04 10:46:04
Headline: CytomX Therapeutics price target raised to $10 from $8 at Barclays
TargetsPT $10.00 | Cons $10.00
UpsideImp +64.7% | Cons +64.7%
Price$14.89
Signal$20.50|-27.4%|2026-02-19 11:28:43
Headline: Grupo Aeromexico price target raised to $32 from $28 at Barclays
TargetsPT $32.00 | Cons $31.33
UpsideImp +56.1% | Cons +52.8%
Price$210.79
Signal$191.16|+10.3%|2026-02-23 15:15:00
Headline: Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA), Expects Beat and Raise Quarter
TargetsPT $400.00 | Cons $272.54
UpsideImp +109.2% | Cons +42.6%
Price$11.68
Signal$15.71|-25.6%|2026-02-23 12:26:14
Headline: PicPay initiated with an Outperform at Mizuho
TargetsPT $30.00 | Cons $23.67
UpsideImp +91.0% | Cons +50.7%
Price$3.36
Signal$5.17|-35.1%|2026-02-23 06:49:00
Headline: Citizens Starts MiMedx Group (MDXG) at Market Outperform
TargetsPT $10.00 | Cons $10.00
UpsideImp +93.4% | Cons +93.4%
Price$9.07
Signal$9.82|-7.6%|2026-02-26 11:05:00
Headline: H.C. Wainwright Upgrades Joby Aviation Inc (JOBY) to Buy
TargetsPT $18.00 | Cons $15.30
UpsideImp +83.3% | Cons +55.8%
Price$53.62
Signal$59.74|-10.2%|2026-03-03 11:12:00
Headline: BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
TargetsPT $105.00 | Cons $85.43
UpsideImp +75.8% | Cons +43.0%
Price$26.80
Signal$27.72|-3.3%|2026-03-04 21:46:00
Headline: Oculis Holding AG (OCS) PT Raised to $50 at Stifel
TargetsPT $50.00 | Cons $45.67
UpsideImp +80.4% | Cons +64.8%
Price$67.08
Signal$60.72|+10.5%|2026-03-04 15:12:00
Headline: Power Solutions (PSIX) PT Raised to $107 at Freedom Capital Markets
TargetsPT $107.00 | Cons $104.26
UpsideImp +76.2% | Cons +71.7%
Price$40.05
Signal$39.62|+1.1%|2026-03-04 11:41:00
Headline: Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright
TargetsPT $70.00 | Cons $74.50
UpsideImp +76.7% | Cons +88.1%
Price$210.79
Signal$180.10|+17.0%|2026-03-05 15:31:00
Headline: NVIDIA (NVDA) PT Raised to $360 at Tigress Financial Partners
TargetsPT $360.00 | Cons $277.82
UpsideImp +99.9% | Cons +54.3%
Price$30.29
Signal$28.78|+5.2%|2026-03-09 12:57:00
Headline: Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX)
TargetsPT $50.00 | Cons $55.33
UpsideImp +73.7% | Cons +92.3%
Price$65.36
Signal$76.88|-15.0%|2026-03-10 14:08:00
Headline: Morgan Stanley Reiterates Overweight Rating on Planet Fitness (PLNT) amid CFO transition
TargetsPT $117.00 | Cons $132.43
UpsideImp +52.2% | Cons +72.3%
Price$24.13
Signal$28.06|-14.0%|2026-03-10 13:24:00
Headline: Cantor Fitzgerald Reiterates Overweight Rating on Septerna Inc (SEPN)
TargetsPT $60.00 | Cons $39.00
UpsideImp +113.8% | Cons +39.0%
Price$12.79
Signal$15.11|-15.3%|2026-03-10 13:18:00
Headline: Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Stifel
TargetsPT $28.00 | Cons $30.43
UpsideImp +85.4% | Cons +101.4%
Price$2.21
Signal$2.52|-12.3%|2026-03-10 12:53:00
Headline: 3D Systems (DDD) PT Raised to $5 at Cantor Fitzgerald Following 'Respectable' Q4 Results
TargetsPT $5.00 | Cons $5.00
UpsideImp +98.4% | Cons +98.4%
Price$51.50
Signal$52.03|-1.0%|2026-03-10 11:21:00
Headline: Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright
TargetsPT $95.00 | Cons $87.11
UpsideImp +82.6% | Cons +67.4%
Price$166.90
Signal$162.32|+2.8%|2026-03-11 14:27:00
Headline: Deutsche Bank Reiterates Buy Rating on Oracle (ORCL) following Q3 results: "plenty to like in this p…
TargetsPT $300.00 | Cons $280.79
UpsideImp +84.8% | Cons +73.0%
Price$4.95
Signal$4.99|-0.8%|2026-03-11 13:17:00
Headline: Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside oppor…
TargetsPT $9.00 | Cons $7.67
UpsideImp +80.4% | Cons +53.7%
Price$9.07
Signal$10.23|-11.3%|2026-03-12 10:44:00
Headline: H.C. Wainwright Reiterates Buy Rating on Joby Aviation Inc (JOBY)
TargetsPT $18.00 | Cons $15.75
UpsideImp +76.0% | Cons +54.0%
Price$6.54
Signal$6.63|-1.4%|2026-03-13 17:28:00
Headline: Clear Street Reiterates Hold Rating on Runway Grouwth Finance Corp. (RWAY): 'We expect near-term por…
TargetsPT $10.00 | Cons $10.83
UpsideImp +50.8% | Cons +63.3%
Price$83.91
Signal$73.27|+14.5%|2026-03-13 16:39:00
Headline: Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer
TargetsPT $140.00 | Cons $136.40
UpsideImp +91.1% | Cons +86.2%
Price$4.41
Signal$4.16|+5.9%|2026-03-13 13:15:00
Headline: Funko (FNKO) PT Raised to $6.50 at Texas Capital Securities
TargetsPT $6.50 | Cons $6.50
UpsideImp +56.3% | Cons +56.3%
Price$5.05
Signal$5.17|-2.4%|2026-03-16 15:22:00
Headline: H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA d…
TargetsPT $10.00 | Cons $10.25
UpsideImp +93.4% | Cons +98.2%
Price$23.67
Signal$23.67|0.0%|2026-03-16 14:42:00
Headline: Jefferies Reiterates Buy Rating on Forgent Power Solutions (FPS): 'encouraged' by performance amid c…
TargetsPT $44.00 | Cons $37.66
UpsideImp +85.9% | Cons +59.1%
Price$3.50
Signal$2.74|+28.0%|2026-03-16 14:21:00
Headline: Leerink Partners Reiterates Outperform Rating on Eledon Pharamceuticals (ELDN)
TargetsPT $5.00 | Cons $5.00
UpsideImp +82.8% | Cons +82.8%
Price$40.05
Signal$34.68|+15.5%|2026-03-18 16:00:00
Headline: BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations
TargetsPT $63.00 | Cons $72.20
UpsideImp +81.7% | Cons +108.2%
Price$13.37
Signal$13.22|+1.2%|2026-04-27 17:21:35
Headline: Intellia Therapeutics price target raised to $35 from $29 at Leerink
TargetsPT $35.00 | Cons $19.40
UpsideImp +164.9% | Cons +46.8%
Price$69.94
Signal$73.05|-4.3%|2026-04-27 12:04:17
Headline: Oklo initiated with a Buy at Tigress Financial
TargetsPT $130.00 | Cons $114.50
UpsideImp +78.0% | Cons +56.7%
Price$2.73
Signal$2.69|+1.3%|2026-04-27 11:04:17
Headline: Quantum eMotion initiated with a Buy at Alliance Global
TargetsPT $5.00 | Cons $5.00
UpsideImp +85.9% | Cons +85.9%
Price$8.63
Signal$8.66|-0.3%|2026-04-27 10:46:46
Headline: Karyopharm price target raised to $16 from $8 at Piper Sandler
TargetsPT $16.00 | Cons $18.75
UpsideImp +84.8% | Cons +116.5%
Price$26.84
Signal$24.98|+7.4%|2026-04-27 10:14:42
Headline: Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright
TargetsPT $45.00 | Cons $42.50
UpsideImp +80.1% | Cons +70.1%
Price$9.88
Signal$10.83|-8.8%|+046027-01-01 08:00
TargetsPT $26.00 | Cons $11.92
UpsideImp +140.1% | Cons +10.1%
Price$23.67
Signal$23.67|0.0%|2026-01-12 13:45:00
Headline: CAE Inc. (CAE:CN) (CAE) PT Raised to Cdn$46 at RBC Capital
TargetsPT $46.00 | Cons $35.19
UpsideImp +94.3% | Cons +48.7%
Price$39.45
Signal$33.91|+16.3%|2026-01-13 10:57:06
Headline: Versant initiated with an Outperform at Wolfe Research
TargetsPT $52.00 | Cons $52.00
UpsideImp +53.3% | Cons +53.3%
Price$30.29
Signal$40.91|-26.0%|2026-01-16 11:33:00
Headline: MBX Biosciences Inc (MBX) PT Raised to $88 at Guggenheim
TargetsPT $88.00 | Cons $50.80
UpsideImp +115.1% | Cons +24.2%
Price$92.98
Signal$98.55|-5.7%|2026-01-16 09:09:00
Headline: Citi Upgrades Endeavour Group Ltd (EDV:AU) to Buy
TargetsPT $200.00 | Cons $106.40
UpsideImp +102.9% | Cons +8.0%
Price$13.37
Signal$13.95|-4.1%|2026-01-28 11:39:00
Headline: Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright
TargetsPT $25.00 | Cons $19.00
UpsideImp +79.3% | Cons +36.2%
Price$12.70
Signal$11.69|+8.6%|2026-01-29 11:08:52
Headline: Korro Bio upgraded to Buy from Neutral at H.C. Wainwright
TargetsPT $20.00 | Cons $19.67
UpsideImp +71.1% | Cons +68.3%
Price$33.53
Signal$26.61|+26.0%|2026-02-02 10:58:25
Headline: Rapport Therapeutics initiated with an Overweight at Wells Fargo
TargetsPT $43.00 | Cons $42.33
UpsideImp +61.6% | Cons +59.1%
Price$82.13
Signal$82.82|-0.8%|2026-02-09 11:07:38
Headline: Robinhood upgraded to Outperform from Peer Perform at Wolfe Research
TargetsPT $125.00 | Cons $143.69
UpsideImp +50.9% | Cons +73.5%
Price$12.70
Signal$11.24|+13.0%|2026-02-18 21:23:00
Headline: Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy
TargetsPT $18.00 | Cons $19.43
UpsideImp +60.2% | Cons +72.9%
Price$4.56
Signal$4.02|+13.4%|2026-02-19 11:55:08
Headline: Fossil initiated with an Outperform at Northland
TargetsPT $7.00 | Cons $7.00
UpsideImp +74.1% | Cons +74.1%
Price$152.11
Signal$76.96|+97.7%|2026-02-23 13:59:06
Headline: Marvell price target raised to $120 from $115 at UBS
TargetsPT $120.00 | Cons $117.68
UpsideImp +55.9% | Cons +52.9%
Price$11.68
Signal$16.15|-27.7%|2026-02-24 11:08:00
Headline: BofA Securities Starts PicPay (PICS) at Buy
TargetsPT $27.00 | Cons $24.50
UpsideImp +67.2% | Cons +51.7%
Price$210.79
Signal$182.02|+15.8%|2026-03-02 15:49:00
Headline: Baird Reiterates Outperform Rating on NVIDIA (NVDA) following Coherent investment
TargetsPT $300.00 | Cons $276.63
UpsideImp +64.8% | Cons +52.0%
Price$21.05
Signal$15.98|+31.7%|2026-03-03 17:00:00
Headline: Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"
TargetsPT $30.00 | Cons $22.89
UpsideImp +87.8% | Cons +43.3%
Price$210.79
Signal$179.72|+17.3%|2026-03-03 14:05:00
Headline: NVIDIA (NVDA) PT Raised to $300 at Wedbush
TargetsPT $300.00 | Cons $277.46
UpsideImp +66.9% | Cons +54.4%
Price$1.87
Signal$5.53|-66.3%|2026-03-05 21:33:00
Headline: Compass Therapeutics (CMPX) PT Raised to $9 at Jefferies
TargetsPT $9.00 | Cons $11.00
UpsideImp +62.7% | Cons +98.9%
Price$82.13
Signal$79.80|+2.9%|2026-03-05 16:46:00
Headline: BofA Securities Reiterates Buy Rating on Robinhood Markets (HOOD) following Take Flight event
TargetsPT $122.00 | Cons $132.13
UpsideImp +52.9% | Cons +65.6%
Price$204.57
Signal$234.34|-12.7%|2026-03-05 15:02:00
Headline: Jefferies Reiterates Buy Rating on HEICO (HEI) following 10-Q
TargetsPT $400.00 | Cons $387.50
UpsideImp +70.7% | Cons +65.4%
Price$152.11
Signal$91.36|+66.5%|2026-03-06 14:44:00
Headline: Marvell (MRVL) PT Raised to $164 at Craig-Hallum
TargetsPT $164.00 | Cons $120.68
UpsideImp +79.5% | Cons +32.1%
Price$5.45
Signal$5.45|-0.1%|2026-03-06 14:19:00
Headline: Benchmark Reiterates Buy Rating on Janus Int'l Group, Inc. (JBI), Estimates Unchanged
TargetsPT $9.00 | Cons $9.00
UpsideImp +65.1% | Cons +65.1%
Price$30.29
Signal$21.69|+39.6%|2026-03-09 16:04:00
Headline: Adeia (ADEA) PT Raised to $40 at Rosenblatt following AMD agreement
TargetsPT $40.00 | Cons $30.00
UpsideImp +84.4% | Cons +38.3%
Price$3.71
Signal$3.71|0.0%|2026-03-10 13:07:00
Headline: DA Davidson Reiterates Neutral Rating on RideNow Group (RDNW) as Momentum Continues
TargetsPT $6.00 | Cons $6.00
UpsideImp +61.7% | Cons +61.7%
Price$10.58
Signal$9.94|+6.4%|2026-03-10 10:16:00
Headline: H.C. Wainwright Reiterates Buy Rating on Ondas Holdings Inc. (ONDS)
TargetsPT $17.00 | Cons $15.63
UpsideImp +71.0% | Cons +57.2%
Price$6.02
Signal$5.58|+7.9%|2026-03-10 10:06:00
Headline: Deutsche Bank Upgrades Teladoc (TDOC) to Buy
TargetsPT $11.00 | Cons $7.90
UpsideImp +97.3% | Cons +41.7%
Price$21.05
Signal$17.04|+23.5%|2026-03-12 21:06:00
Headline: Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho
TargetsPT $31.00 | Cons $24.50
UpsideImp +81.9% | Cons +43.8%
Price$26.29
Signal$26.19|+0.4%|2026-03-12 14:23:00
Headline: UBS Reiterates Buy Rating on Life Time Group Holdings Inc (LTH)
TargetsPT $43.00 | Cons $41.33
UpsideImp +64.2% | Cons +57.8%
Price$210.79
Signal$184.43|+14.3%|2026-03-12 13:28:00
Headline: Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA) Ahead of GTC Event
TargetsPT $300.00 | Cons $278.59
UpsideImp +62.7% | Cons +51.1%
Price$84.94
Signal$90.02|-5.6%|2026-03-12 09:56:00
Headline: Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo
TargetsPT $143.00 | Cons $140.18
UpsideImp +58.9% | Cons +55.7%
Price$7.09
Signal$5.91|+20.0%|2026-03-13 18:49:00
Headline: Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotuni…
TargetsPT $10.00 | Cons $9.00
UpsideImp +69.2% | Cons +52.3%
Price$110.34
Signal$107.97|+2.2%|2026-03-13 17:09:00
Headline: Stifel Reiterates Buy Rating on Colliers International (CIGI) amid Savills acquisition of Eastdil
TargetsPT $175.00 | Cons $182.60
UpsideImp +62.1% | Cons +69.1%
Price$75.32
Signal$38.01|+98.1%|2026-03-13 13:26:00
Headline: BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Thr…
TargetsPT $73.00 | Cons $55.86
UpsideImp +92.0% | Cons +47.0%
Price$34.21
Signal$33.42|+2.4%|2026-03-13 11:30:00
Headline: Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result
TargetsPT $62.00 | Cons $47.75
UpsideImp +85.5% | Cons +42.9%
Price$54.58
Signal$54.02|+1.0%|2026-03-13 11:22:00
Headline: Rubrik (RBRK) Reiterated at Overweight by Cantor Fitzgerald After Q4 Results
TargetsPT $85.00 | Cons $92.17
UpsideImp +57.3% | Cons +70.6%
Price$45.67
Signal$35.10|+30.1%|2026-03-13 11:14:00
Headline: Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet
TargetsPT $60.00 | Cons $55.25
UpsideImp +70.9% | Cons +57.4%
Price$10.94
Signal$10.90|+0.4%|2026-03-13 10:43:00
Headline: Elicio Therapeutics (ELTX) PT Raised to $17 at H.C. Wainwright
TargetsPT $17.00 | Cons $17.00
UpsideImp +56.0% | Cons +56.0%
Price$192.81
Signal$180.85|+6.6%|2026-03-16 13:53:00
Headline: Jefferies Reiterates Buy Rating on Capital One Financial (COF) after Feb credit metrics
TargetsPT $300.00 | Cons $275.50
UpsideImp +65.9% | Cons +52.3%
Price$20.40
Signal$20.81|-2.0%|2026-04-27 11:59:09
Headline: TeraWulf price target raised to $41.50 from $37 at Morgan Stanley
TargetsPT $41.50 | Cons $26.47
UpsideImp +99.5% | Cons +27.2%
Price$4.23
Signal$4.70|-10.0%|2026-04-27 11:33:01
Headline: Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
TargetsPT $8.00 | Cons $8.00
UpsideImp +70.2% | Cons +70.2%
Price$23.67
Signal$23.67|0.0%|2026-01-13 13:16:00
Headline: BCE Inc. (BCE:CN) (BCE) PT Raised to Cdn$38 at RBC Capital
TargetsPT $38.00 | Cons $33.86
UpsideImp +60.5% | Cons +43.1%
Price$29.01
Signal$24.66|+17.6%|2026-01-30 14:20:35
Headline: SSR Mining price target raised to $38.50 from $34.50 at UBS
TargetsPT $38.50 | Cons $33.50
UpsideImp +56.1% | Cons +35.8%
Price$110.34
Signal$128.34|-14.0%|2026-02-04 12:19:53
Headline: Colliers International upgraded to Strong Buy from Outperform at Raymond James
TargetsPT $200.00 | Cons $188.00
UpsideImp +55.8% | Cons +46.5%
Price$20.13
Signal$20.08|+0.2%|2026-02-04 10:47:44
Headline: Capri Holdings price target raised to $32 from $31 at Barclays
TargetsPT $32.00 | Cons $25.73
UpsideImp +59.4% | Cons +28.1%
Price$53.62
Signal$42.43|+26.4%|2026-02-10 12:23:59
Headline: Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel
TargetsPT $66.00 | Cons $55.75
UpsideImp +55.6% | Cons +31.4%
Price$14.89
Signal$19.02|-21.7%|2026-02-10 10:44:20
Headline: Grupo Aeromexico price target raised to $28 from $27 at Barclays
TargetsPT $28.00 | Cons $30.67
UpsideImp +47.2% | Cons +61.3%
Price$134.10
Signal$97.52|+37.5%|2026-02-18 10:17:21
Headline: Nebius initiated with a Buy at Compass Point
TargetsPT $150.00 | Cons $141.20
UpsideImp +53.8% | Cons +44.8%
Price$162.56
Signal$127.43|+27.6%|2026-02-24 05:23:00
Headline: Evercore ISI Reiterates Outperform Rating on Arista Networks (ANET)
TargetsPT $200.00 | Cons $183.00
UpsideImp +56.9% | Cons +43.6%
Price$53.62
Signal$60.26|-11.0%|2026-02-26 13:22:00
Headline: BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
TargetsPT $104.00 | Cons $82.00
UpsideImp +72.6% | Cons +36.1%
Price$183.05
Signal$191.75|-4.5%|2026-02-26 11:29:00
Headline: Goldman Sachs Reiterates Buy Rating on salesforce.com (CRM)
TargetsPT $281.00 | Cons $299.00
UpsideImp +46.5% | Cons +55.9%
Price$53.62
Signal$60.47|-11.3%|2026-03-02 14:53:00
Headline: BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
TargetsPT $105.00 | Cons $85.43
UpsideImp +73.6% | Cons +41.3%
Price$75.97
Signal$74.40|+2.1%|2026-03-05 14:22:00
Headline: DA Davidson Reiterates Buy Rating on Euronet Worldwide (EEFT)
TargetsPT $112.00 | Cons $103.00
UpsideImp +50.5% | Cons +38.4%
Price$76.97
Signal$81.16|-5.2%|2026-03-06 13:03:00
Headline: Okta, Inc (OKTA) PT Raised to $134 at Bernstein SocGen Group
TargetsPT $134.00 | Cons $108.24
UpsideImp +65.1% | Cons +33.4%
Price$53.62
Signal$62.76|-14.6%|2026-03-09 19:52:00
Headline: Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies
TargetsPT $100.00 | Cons $76.67
UpsideImp +59.3% | Cons +22.2%
Price$84.55
Signal$80.88|+4.5%|2026-03-09 14:15:00
Headline: Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer
TargetsPT $145.00 | Cons $101.00
UpsideImp +79.3% | Cons +24.9%
Price$33.53
Signal$29.97|+11.9%|2026-03-09 13:49:00
Headline: BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no rea…
TargetsPT $47.00 | Cons $43.50
UpsideImp +56.8% | Cons +45.2%
Price$23.68
Signal$28.10|-15.7%|2026-03-10 20:05:00
Headline: Raymond James Starts Alumis Inc (ALMS) at Strong Buy
TargetsPT $46.00 | Cons $38.44
UpsideImp +63.7% | Cons +36.8%
Price$14.40
Signal$13.50|+6.7%|2026-03-11 13:46:00
Headline: UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders
TargetsPT $21.00 | Cons $18.85
UpsideImp +55.6% | Cons +39.7%
Price$6.63
Signal$7.00|-5.3%|2026-03-12 18:55:00
Headline: Truist Securities Reiterates Hold Rating on Aveanna Healthcare Holdings Inc (AVAH) amid acquisition
TargetsPT $10.00 | Cons $11.25
UpsideImp +42.9% | Cons +60.7%
Price$36.38
Signal$38.39|-5.2%|2026-03-12 13:55:00
Headline: BofA Securities Reiterates Buy Rating on Dynatrace Inc. (DT): "risk/reward is very attractive"
TargetsPT $64.00 | Cons $51.47
UpsideImp +66.7% | Cons +34.1%
Price$53.62
Signal$59.86|-10.4%|2026-03-12 13:26:00
Headline: Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a…
TargetsPT $103.00 | Cons $86.60
UpsideImp +72.1% | Cons +44.7%
Price$134.10
Signal$130.55|+2.7%|2026-03-16 16:12:00
Headline: Nebius Group (NBIS) PT Raised to $200 at DA Davidson
TargetsPT $200.00 | Cons $176.60
UpsideImp +53.2% | Cons +35.3%
Price$12.18
Signal$11.52|+5.7%|2026-03-17 13:57:00
Headline: Craig-Hallum stays Buy on Green Dot (GDOT): 'opportunity' as current stock indicates 0.68x TBV multi…
TargetsPT $18.00 | Cons $16.13
UpsideImp +56.3% | Cons +40.0%
Price$32.96
Signal$43.91|-24.9%|2026-03-17 12:42:00
Headline: Morgan Stanley stays Overweight on Celsius Holdings (CELH), estimates Alani growth in mid-80%s
TargetsPT $64.00 | Cons $67.25
UpsideImp +45.8% | Cons +53.2%
Price$41.52
Signal$44.76|-7.2%|2026-03-18 14:59:00
Headline: GDS Holdings (GDS) PT Raised to $67.50 at Macquarie as Chinese hyperscalers step up CapEx commitment…
TargetsPT $67.50 | Cons $62.17
UpsideImp +50.8% | Cons +38.9%
Price$48.98
Signal$49.94|-1.9%|2026-04-27 13:40:55
Headline: Goosehead Insurance price target raised to $85 from $81 at UBS
TargetsPT $85.00 | Cons $67.14
UpsideImp +70.2% | Cons +34.4%
Price$19.69
Signal$20.97|-6.1%|2026-04-27 11:44:37
Headline: QXO price target raised to $32 from $30 at Oppenheimer
TargetsPT $32.00 | Cons $30.20
UpsideImp +52.6% | Cons +44.0%
Price$174.04
Signal$175.23|-0.7%|2026-04-27 09:59:01
Headline: SAP price target raised to $257 from $256 at Barclays
TargetsPT $257.00 | Cons $391.67
UpsideImp +46.7% | Cons +123.5%
Price$20.47
Signal$20.13|+1.7%|2026-04-27 08:59:20
Headline: HMH Holding initiated with an Overweight at Piper Sandler
TargetsPT $32.00 | Cons $28.67
UpsideImp +59.0% | Cons +42.4%
| ZVRA | Zevra Therapeutics, Inc. | Healthcare | Biotechnology | $584.6M | N/A | $26.00 | $8.90 | +194.8% | $24.67 | +179.7% | +12.1% | +046022-01 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.6B | N/A | $15.00 | $5.89 | +150.8% | $13.50 | +125.8% | +70.3% | +046022-01 | |
| ALMS | Alumis Inc. Common Stock | Healthcare | Biotechnology | $2.9B | Alumis price target raised to $50 from $25 at Oppenheimer | $50.00 | $17.93 | +208.1% | $34.33 | +111.5% | +45.9% | 2026-01-06 | |
| ARDX | Ardelyx, Inc. | Healthcare | Biotechnology | $1.5B | Ardelyx price target raised to $19 from $16 at Raymond James | $19.00 | $7.75 | +171.6% | $15.60 | +123.0% | -14.2% | 2026-01-08 | |
| CGEM | Cullinan Therapeutics, Inc. | Healthcare | Medical - Pharmaceuticals | $774.1M | Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright | $27.00 | $11.13 | +150.7% | $31.00 | +187.8% | +18.8% | 2026-01-08 | |
| BRCC | BRC Inc. | Consumer Defensive | Packaged Foods | $356.3M | DA Davidson Reiterates Buy Rating on BRC Inc. (BRCC) | $2.50 | $0.97 | +151.6% | $2.50 | +151.6% | +13.2% | 2026-01-14 | |
| LEGN | Legend Biotech Corporation | Healthcare | Biotechnology | $4.3B | FDA draft guidance favorable for Legend Biotech, says RBC Capital | $66.00 | $23.42 | +180.6% | $62.17 | +164.3% | -1.6% | 2026-01-20 | |
| ATAI | Atai Beckley N.V | Healthcare | Medical - Pharmaceuticals | $806.4M | Atai Beckley initiated with a Buy at Guggenheim | $11.00 | $3.85 | +202.2% | $12.33 | +238.7% | +17.4% | 2026-01-20 | |
| IRD | Opus Genetics, Inc. | Healthcare | Biotechnology | $353.6M | Opus Genetics initiated with a Buy at BTIG | $7.00 | $2.26 | +233.3% | $7.00 | +233.3% | +135.8% | 2026-01-20 | |
| ARCT | Arcturus Therapeutics Holdings Inc. | Healthcare | Biotechnology | $249.7M | Arcturus Therapeutics initiated with a Buy at Roth Capital | $20.00 | $7.59 | +163.5% | $37.00 | +387.5% | +15.7% | 2026-01-22 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $1.2B | GH Research price target raised to $40 from $33 at RBC Capital | $40.00 | $16.73 | +139.1% | $35.17 | +110.2% | +15.3% | 2026-01-23 | |
| RLMD | Relmada Therapeutics, Inc. | Healthcare | Biotechnology | $520.0M | Relmada Therapeutics assumed at Outperform from Market Perform at Leerink | $8.00 | $3.90 | +102.0% | $8.50 | +114.6% | +79.1% | 2026-01-23 | |
| NKTR | Nektar Therapeutics | Healthcare | Biotechnology | $1.7B | Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' | $105.00 | $37.18 | +188.9% | $119.00 | +227.4% | +130.8% | 2026-01-26 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.4M | Korro Bio upgraded to Overweight from Neutral at Piper Sandler | $30.00 | $11.69 | +156.6% | $19.67 | +68.3% | +8.6% | 2026-01-28 | |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | Biotechnology | $3.2B | Dianthus price target raised to $125 from $62 at Oppenheimer | $125.00 | $53.36 | +134.8% | $80.20 | +50.7% | +58.8% | 2026-01-29 | |
| CATX | Perspective Therapeutics, Inc. | Healthcare | Medical - Devices | $299.8M | Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright | $12.00 | $3.79 | +181.7% | $11.00 | +158.2% | -4.5% | 2026-01-30 | |
| ENGN | enGene Holdings Inc. | Healthcare | Biotechnology | $350.9M | enGene initiated with a Buy at Jefferies | $28.00 | $9.53 | +172.6% | $24.00 | +133.7% | -33.3% | 2026-01-30 | |
| CGEM | Cullinan Therapeutics, Inc. | Healthcare | Medical - Pharmaceuticals | $774.1M | Cullinan Therapeutics initiated with a Buy at Guggenheim | $30.00 | $12.71 | +150.8% | $30.83 | +157.8% | +6.9% | 2026-02-02 | |
| APP | AppLovin Corporation | Technology | Software - Application | $150.1B | AppLovin derating creates potential opportunity, says Morgan Stanley | $800.00 | $387.34 | +106.5% | $755.85 | +95.1% | +15.3% | 2026-02-04 | |
| CMPX | Compass Therapeutics, Inc. | Healthcare | Biotechnology | $257.9M | Compass Therapeutics price target raised to $13 from $10 at Canaccord | $13.00 | $6.33 | +102.5% | $10.50 | +63.6% | -71.0% | 2026-02-04 | |
| CIFR | Cipher Mining Inc. | Financial Services | Financial - Capital Markets | $6.8B | Cipher Mining initiated with an Overweight at Morgan Stanley | $38.00 | $16.76 | +158.0% | $26.31 | +78.6% | +14.2% | 2026-02-09 | |
| WULF | TeraWulf Inc. | Financial Services | Financial - Capital Markets | $8.1B | TeraWulf initiated with an Overweight at Morgan Stanley | $37.00 | $16.65 | +158.9% | $22.50 | +57.5% | +42.7% | 2026-02-09 | |
| NKTR | Nektar Therapeutics | Healthcare | Biotechnology | $1.7B | Nektar price target raised to $165 from $135 at H.C. Wainwright | $165.00 | $56.00 | +213.6% | $131.40 | +149.7% | +59.5% | 2026-02-10 | |
| HOOD | Robinhood Markets, Inc. | Financial Services | Financial - Capital Markets | $73.9B | Bernstein Reiterates Outperform Rating on Robinhood Markets (HOOD) | $160.00 | $78.07 | +110.8% | $137.71 | +81.4% | +8.2% | 2026-02-11 | |
| APP | AppLovin Corporation | Technology | Software - Application | $150.1B | AppLovin price target raised to $775 from $750 at Scotiabank | $775.00 | $366.91 | +108.2% | $690.93 | +85.6% | +19.9% | 2026-02-12 | |
| IMDX | Insight Molecular Diagnostics Inc. | Healthcare | Biotechnology | $114.1M | Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street | $12.00 | $5.39 | +125.1% | $10.50 | +97.0% | -20.3% | 2026-02-17 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.6B | Vir Biotechnology price target raised to $26 from $24 at Barclays | $26.00 | $7.50 | +248.1% | $20.50 | +174.4% | +36.3% | 2026-02-17 | |
| VSTM | Verastem, Inc. | Healthcare | Biotechnology | $375.8M | Verastem price target raised to $18 from $15 at Mizuho | $18.00 | $5.94 | +215.2% | $15.00 | +162.7% | -5.1% | 2026-02-19 | |
| NBIS | Nebius Group N.V. | Communication Services | Internet Content & Information | $32.2B | Nebius price target raised to $232 from $211 at Northland | $232.00 | $100.61 | +133.7% | $156.33 | +57.4% | +35.1% | 2026-02-23 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.6B | Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley | $24.00 | $10.42 | +223.0% | $20.67 | +178.2% | +37.1% | 2026-02-24 | |
| PLNT | Planet Fitness, Inc. | Consumer Cyclical | Leisure | $5.2B | Jefferies trims Planet Fitness price target, sees 'strong buying opportunity' | $175.00 | $79.87 | +111.8% | $134.00 | +62.2% | -20.9% | 2026-02-24 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.6B | Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners | $20.00 | $9.32 | +114.5% | $20.57 | +120.6% | +9.2% | 2026-02-26 | |
| SGRY | Surgery Partners, Inc. | Healthcare | Medical - Care Facilities | $1.9B | Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results | $30.00 | $13.92 | +123.7% | $22.33 | +66.5% | +7.3% | 2026-03-03 | |
| DKNG | DraftKings Inc. | Consumer Cyclical | Gambling, Resorts & Casinos | $11.7B | DraftKings Inc. (DKNG) PT Raised to $50 at BMO Capital, Top Pick | $50.00 | $24.45 | +109.9% | $37.61 | +57.9% | -1.0% | 2026-03-03 | |
| ARCT | Arcturus Therapeutics Holdings Inc. | Healthcare | Biotechnology | $249.7M | '2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler | $25.00 | $7.33 | +236.9% | $22.50 | +203.2% | +18.4% | 2026-03-04 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.6B | Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright | $20.00 | $9.25 | +119.1% | $21.29 | +133.2% | +11.6% | 2026-03-04 | |
| SOC | Sable Offshore Corp. | Energy | Oil & Gas Drilling | $1.3B | Jefferies Reiterates Buy Rating on Sable Offshore Corp. (SOC) amid DOJ formal opinion | $28.00 | $13.85 | +115.2% | $27.00 | +107.5% | +1.3% | 2026-03-05 | |
| VSTM | Verastem, Inc. | Healthcare | Biotechnology | $375.8M | Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026" | $19.00 | $6.15 | +207.4% | $16.00 | +158.9% | -12.3% | 2026-03-05 | |
| RGTI | Rigetti Computing, Inc. | Technology | Computer Hardware | $5.5B | Rosenblatt Reiterates Buy Rating on Rigetti Computing Inc. (RGTI), raises rev estimate | $40.00 | $16.97 | +142.2% | $38.33 | +132.1% | -0.6% | 2026-03-05 | |
| ATAI | Atai Beckley N.V | Healthcare | Medical - Pharmaceuticals | $806.4M | Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Phase IIb TRD results" | $10.00 | $3.39 | +195.0% | $11.75 | +246.6% | +26.1% | 2026-03-06 | |
| JBIO | Jade Biosciences, Inc. | Healthcare | Biotechnology | $875.5M | Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101" | $40.00 | $14.05 | +184.4% | $31.00 | +120.4% | +90.8% | 2026-03-06 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | Badger Infrastructure Solutions Ltd (BDGI:CN) (BADFF) PT Lowered at BMO Capital | $80.00 | $23.67 | +238.0% | $43.52 | +83.9% | 0.0% | 2026-03-06 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $1.2B | GH Research PLC (GHRS) PT Raised to $32 at Needham | $32.00 | $15.93 | +108.7% | $35.67 | +132.6% | +25.8% | 2026-03-06 | |
| EDIT | Editas Medicine, Inc. | Healthcare | Biotechnology | $299.0M | Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings | $6.00 | $2.32 | +158.6% | $6.00 | +158.6% | +31.7% | 2026-03-09 | |
| QURE | uniQure N.V. | Healthcare | Biotechnology | $1.1B | Wells Fargo Upgrades uniQure BV (QURE) to Overweight | $60.00 | $17.99 | +239.3% | $41.80 | +136.4% | +1.9% | 2026-03-09 | |
| KLRS | Kalaris Therapeutics Inc | Healthcare | Biotechnology | $104.3M | Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS) | $23.00 | $10.00 | +141.8% | $21.00 | +120.8% | -41.4% | 2026-03-09 | |
| ENGN | enGene Holdings Inc. | Healthcare | Biotechnology | $350.9M | Raymond James Reiterates Strong Buy Rating on Engene Holdings Inc. (ENGN) following Q1 results | $27.00 | $7.05 | +246.6% | $24.60 | +215.8% | -12.0% | 2026-03-09 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | AltaGas Ltd. (ALA:CN) (ATGFF) PT Raised to Cdn$49 at BMO Capital | $49.00 | $23.67 | +107.0% | $39.09 | +65.1% | 0.0% | 2026-03-09 | |
| CLYM | Climb Bio, Inc. | Healthcare | Biotechnology | $634.7M | Raymond James Starts Climb Bio (CLYM) at Strong Buy | $25.00 | $7.33 | +241.1% | $18.00 | +145.6% | +27.0% | 2026-03-10 | |
| BNTX | BioNTech SE | Healthcare | Biotechnology | $25.4B | Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes | $155.00 | $83.89 | +84.8% | $138.71 | +65.3% | +20.4% | 2026-03-10 | |
| QTTB | Q32 Bio Inc. | Healthcare | Biotechnology | $69.1M | H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key clinical data" | $13.00 | $5.99 | +117.0% | $13.00 | +117.0% | -6.2% | 2026-03-10 | |
| LEGN | Legend Biotech Corporation | Healthcare | Biotechnology | $4.3B | Truist Securities Reiterates Buy Rating on Legend Biotech Corp. (LEGN): "infer from comments that Raritan's full manufacturing slot capacity approved" | $70.00 | $19.56 | +257.9% | $58.60 | +199.6% | +18.3% | 2026-03-10 | |
| JMIA | Jumia Technologies AG | Consumer Cyclical | Specialty Retail | $427.3M | Craig-Hallum Reiterates Buy Rating on Jumia Technologies (JMIA): "we expect quarters to start to stack" | $18.00 | $7.93 | +122.1% | $17.33 | +113.8% | -14.9% | 2026-03-10 | |
| RPAY | Repay Holdings Corporation | Technology | Software - Infrastructure | $356.4M | DA Davidson Reiterates Buy Rating on Repay (RPAY) Following Q4 Results | $9.00 | $3.04 | +187.1% | $6.83 | +117.9% | +30.0% | 2026-03-10 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $1.2B | GH Research PLC (GHRS) PT Raised to $34 at Guggenheim | $34.00 | $15.76 | +115.0% | $36.50 | +130.9% | +22.0% | 2026-03-10 | |
| ZVRA | Zevra Therapeutics, Inc. | Healthcare | Biotechnology | $584.6M | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim | $23.00 | $11.06 | +108.5% | $24.25 | +119.9% | -10.3% | 2026-03-10 | |
| SPRY | ARS Pharmaceuticals, Inc. | Healthcare | Biotechnology | $783.0M | ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners | $26.00 | $8.86 | +180.2% | $29.33 | +216.1% | -15.0% | 2026-03-10 | |
| MLYS | Mineralys Therapeutics, Inc. | Healthcare | Biotechnology | $1.7B | H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS) | $56.00 | $28.43 | +105.7% | $54.00 | +98.3% | -5.3% | 2026-03-10 | |
| ARDX | Ardelyx, Inc. | Healthcare | Biotechnology | $1.5B | Leerink Partners Reiterates Outperform Rating on Ardelyx, Inc (ARDX) following conference | $17.00 | $5.66 | +200.3% | $17.00 | +200.4% | +6.1% | 2026-03-12 | |
| VKTX | Viking Therapeutics, Inc. | Healthcare | Biotechnology | $3.8B | Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year" | $101.00 | $35.47 | +184.8% | $103.00 | +190.4% | -6.7% | 2026-03-12 | |
| LXRX | Lexicon Pharmaceuticals, Inc. | Healthcare | Biotechnology | $708.0M | H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX): "significant upside potential exists" | $6.00 | $1.72 | +252.5% | $6.00 | +252.5% | -1.8% | 2026-03-12 | |
| PHAR | Pharming Group N.V. | Healthcare | Biotechnology | $1.2B | H.C. Wainwright Reiterates Buy Rating on Pharming Group (PHAR): "well positioned to drive value" | $37.00 | $15.14 | +137.5% | $39.50 | +153.5% | +5.8% | 2026-03-12 | |
| RARE | Ultragenyx Pharmaceutical Inc. | Healthcare | Biotechnology | $2.4B | Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clinical win" | $60.00 | $21.71 | +180.9% | $49.90 | +133.6% | +16.2% | 2026-03-12 | |
| TNYA | Tenaya Therapeutics, Inc. | Healthcare | Biotechnology | $115.7M | Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "remains on track to share interim data" | $2.00 | $0.89 | +110.5% | $2.33 | +145.3% | -26.9% | 2026-03-12 | |
| LFMD | LifeMD, Inc. | Healthcare | Medical - Pharmaceuticals | $218.8M | LifeMD Inc (LFMD) PT Raised to $10 at Freedom Capital Markets | $10.00 | $3.94 | +157.7% | $8.50 | +119.1% | +17.5% | 2026-03-12 | |
| CDXS | Codexis, Inc. | Healthcare | Biotechnology | $247.6M | Stifel Reiterates Buy Rating on Codexis, Inc. (CDXS): "remains an interesting small cap idea" | $5.00 | $1.71 | +194.1% | $5.00 | +194.1% | +60.3% | 2026-03-12 | |
| SANA | Sana Biotechnology, Inc. | Healthcare | Biotechnology | $887.3M | Morgan Stanley Reiterates Overweight Rating on Sana Biotechnology (SANA) after "meaningful platform level de-risking event" | $12.00 | $3.36 | +257.1% | $9.00 | +167.9% | -1.0% | 2026-03-13 | |
| SOTK | Sono-Tek Corporation | Technology | Hardware, Equipment & Parts | $72.7M | Sono-Tek (SOTK) PT Raised to $8.50 at Oak Ridge Financial | $8.50 | $4.19 | +102.9% | $8.50 | +102.9% | +10.5% | 2026-03-13 | |
| LPRO | Open Lending Corporation | Financial Services | Financial - Credit Services | $200.4M | DA Davidson Reiterates Buy Rating on Open Lending (LPRO) | $4.00 | $1.45 | +176.8% | $4.00 | +176.8% | +17.3% | 2026-03-13 | |
| COWN | Cowen Inc. | Financial Services | Financial - Capital Markets | $1.1B | ServiceTitan (TTAN) PT Raised to $135 at TD Cowen | $135.00 | $38.99 | +246.2% | $106.67 | +173.6% | 0.0% | 2026-03-13 | |
| CNTY | Century Casinos, Inc. | Consumer Cyclical | Gambling, Resorts & Casinos | $40.2M | Stifel Reiterates Buy Rating on Century Casinos (CNTY) following Q4 report | $3.00 | $1.31 | +117.4% | $2.50 | +81.2% | +1.8% | 2026-03-13 | |
| ACIU | AC Immune S.A. | Healthcare | Biotechnology | $306.3M | Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial' | $7.00 | $3.02 | +132.9% | $7.00 | +132.9% | +0.2% | 2026-03-13 | |
| RLAY | Relay Therapeutics, Inc. | Healthcare | Biotechnology | $2.4B | Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim | $22.00 | $10.36 | +103.4% | $16.33 | +51.0% | +21.7% | 2026-03-13 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.4M | Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform | $23.00 | $12.80 | +100.0% | $20.29 | +76.4% | +10.4% | 2026-03-13 | |
| PRTA | Prothena Corporation plc | Healthcare | Biotechnology | $602.8M | Prothena (PRTA) Reiterated at Market Outperform by Citizens After Fireside Chat | $19.00 | $9.21 | +104.1% | $24.83 | +166.7% | +20.3% | 2026-03-13 | |
| VNET | VNET Group, Inc. | Technology | Information Technology Services | $2.2B | VNET Group Inc (VNET) PT Raised to $23.55 at Jefferies, 'Growth to Accelerate', 'Still our top pick' | $23.55 | $9.53 | +149.2% | $23.55 | +149.2% | -11.6% | 2026-03-16 | |
| NBP | NovaBridge Biosciences | Healthcare | Biotechnology | $277.2M | H.C. Wainwright Reiterates Buy Rating on NovaBridge Biosciences (NBP) following FDA meeting feedback | $9.00 | $2.90 | +214.7% | $9.00 | +214.7% | -15.9% | 2026-03-16 | |
| CLYM | Climb Bio, Inc. | Healthcare | Biotechnology | $634.7M | Truist Securities Starts Climb Bio (CLYM) at Buy | $17.00 | $7.12 | +138.8% | $17.67 | +148.2% | +30.7% | 2026-03-17 | |
| CATX | Perspective Therapeutics, Inc. | Healthcare | Medical - Devices | $299.8M | Truist Reiterates Buy Rating on Perspective Therapeutics Inc (CATX) | $12.00 | $4.95 | +135.8% | $12.20 | +139.7% | -20.0% | 2026-03-17 | |
| GPCR | Structure Therapeutics Inc. | Healthcare | Biotechnology | $2.6B | Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital | $145.00 | $56.15 | +154.9% | $116.71 | +105.2% | -21.4% | 2026-03-17 | |
| BCYC | Bicycle Therapeutics plc | Healthcare | Biotechnology | $327.3M | Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right call' | $13.00 | $5.07 | +153.4% | $11.00 | +114.4% | -7.9% | 2026-03-17 | |
| CTMX | CytomX Therapeutics, Inc. | Healthcare | Biotechnology | $710.8M | CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here' | $16.00 | $4.40 | +247.4% | $11.60 | +151.9% | -9.3% | 2026-03-18 | |
| ORKA | Oruka Therapeutics, Inc. | Healthcare | Biotechnology | $2.8B | Oruka Therapeutics price target raised to $200 from $125 at Guggenheim | $200.00 | $76.38 | +146.6% | $141.83 | +74.9% | -7.1% | 2026-04-27 | |
| SPRB | Spruce Biosciences, Inc. | Healthcare | Biotechnology | $74.9M | Spruce Biosciences initiated with a Buy at Craig-Hallum | $140.00 | $55.50 | +151.7% | $227.33 | +308.6% | -1.9% | 2026-04-27 | |
| CIFR | Cipher Mining Inc. | Financial Services | Financial - Capital Markets | $6.8B | Cipher Mining price target raised to $40.50 from $38 at Morgan Stanley | $40.50 | $16.98 | +119.5% | $27.86 | +51.0% | -8.9% | 2026-04-27 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.3B | BioMarin resumed with an Overweight at Morgan Stanley | $120.00 | $53.59 | +125.7% | $89.64 | +68.6% | +0.8% | 2026-04-27 | |
| GPCR | Structure Therapeutics Inc. | Healthcare | Biotechnology | $2.6B | Structure Therapeutics initiated with a Buy at Canaccord | $101.00 | $45.57 | +122.0% | $114.75 | +152.3% | -1.8% | 2026-04-27 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $1.2B | Guggenheim Reiterates Buy Rating on GH Research PLC (GHRS) Post Mgmt Call | $29.00 | $13.68 | +83.5% | $34.20 | +116.4% | +22.0% | 2026-01-05 | |
| CMPX | Compass Therapeutics, Inc. | Healthcare | Biotechnology | $257.9M | Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) | $9.00 | $5.46 | +84.0% | $9.67 | +97.7% | -61.9% | 2026-01-06 | |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | Biotechnology | $3.2B | Dianthus price target raised to $63 from $56 at Truist | $63.00 | $38.96 | +65.4% | $69.00 | +81.1% | +122.0% | 2026-01-08 | |
| ONDS | Ondas Holdings Inc. | Technology | Communication Equipment | $5.1B | Ondas price target raised to $25 from $12 at H.C. Wainwright | $25.00 | $13.13 | +106.0% | $16.43 | +35.4% | -12.9% | 2026-01-20 | |
| CTMX | CytomX Therapeutics, Inc. | Healthcare | Biotechnology | $710.8M | CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler | $10.00 | $5.37 | +85.5% | $8.75 | +62.3% | -22.5% | 2026-01-20 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.3B | BioMarin upgraded to Buy from Hold at Canaccord | $98.00 | $56.31 | +79.5% | $82.92 | +51.9% | -1.8% | 2026-01-20 | |
| RLAY | Relay Therapeutics, Inc. | Healthcare | Biotechnology | $2.4B | Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer | $14.00 | $7.59 | +88.4% | $13.50 | +81.7% | +77.1% | 2026-01-26 | |
| MBX | MBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | $1.0B | MBX Biosciences initiated with an Overweight at Barclays | $66.00 | $36.07 | +83.0% | $53.33 | +47.9% | -16.0% | 2026-01-27 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.4M | Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald | $21.00 | $10.74 | +95.5% | $21.50 | +100.2% | +18.2% | 2026-01-27 | |
| ARDX | Ardelyx, Inc. | Healthcare | Biotechnology | $1.5B | Ardelyx price target raised to $15 from $8 at Jefferies | $15.00 | $7.89 | +92.3% | $15.50 | +98.7% | -23.0% | 2026-01-27 | |
| CTMX | CytomX Therapeutics, Inc. | Healthcare | Biotechnology | $710.8M | CytomX Therapeutics price target raised to $10 from $8 at Barclays | $10.00 | $5.67 | +64.7% | $10.00 | +64.7% | -31.2% | 2026-02-04 | |
| AERO | Grupo Aeroméxico, S.A.B. de C.V. | Industrials | Airlines, Airports & Air Services | $2.2B | Grupo Aeromexico price target raised to $32 from $28 at Barclays | $32.00 | $20.51 | +56.1% | $31.33 | +52.8% | -27.4% | 2026-02-19 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $5.1T | Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA), Expects Beat and Raise Quarter | $400.00 | $191.55 | +109.2% | $272.54 | +42.6% | +10.3% | 2026-02-23 | |
| PICS | PicS N.V. | Technology | Software - Infrastructure | $1.5B | PicPay initiated with an Outperform at Mizuho | $30.00 | $15.61 | +91.0% | $23.67 | +50.7% | -25.6% | 2026-02-23 | |
| MDXG | MiMedx Group, Inc. | Healthcare | Biotechnology | $498.4M | Citizens Starts MiMedx Group (MDXG) at Market Outperform | $10.00 | $5.33 | +93.4% | $10.00 | +93.4% | -35.1% | 2026-02-23 | |
| JOBY | Joby Aviation, Inc. | Industrials | Airlines, Airports & Air Services | $8.9B | H.C. Wainwright Upgrades Joby Aviation Inc (JOBY) to Buy | $18.00 | $10.23 | +83.3% | $15.30 | +55.8% | -7.6% | 2026-02-26 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.3B | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays | $105.00 | $58.53 | +75.8% | $85.43 | +43.0% | -10.2% | 2026-03-03 | |
| OCS | Oculis Holding AG | Healthcare | Biotechnology | $1.5B | Oculis Holding AG (OCS) PT Raised to $50 at Stifel | $50.00 | $28.40 | +80.4% | $45.67 | +64.8% | -3.3% | 2026-03-04 | |
| PSIX | Power Solutions International, Inc. | Industrials | Industrial - Machinery | $1.5B | Power Solutions (PSIX) PT Raised to $107 at Freedom Capital Markets | $107.00 | $59.58 | +76.2% | $104.26 | +71.7% | +10.5% | 2026-03-04 | |
| HROW | Harrow Health, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.5B | Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright | $70.00 | $38.63 | +76.7% | $74.50 | +88.1% | +1.1% | 2026-03-04 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $5.1T | NVIDIA (NVDA) PT Raised to $360 at Tigress Financial Partners | $360.00 | $183.34 | +99.9% | $277.82 | +54.3% | +17.0% | 2026-03-05 | |
| MBX | MBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | $1.0B | Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX) | $50.00 | $27.94 | +73.7% | $55.33 | +92.3% | +5.2% | 2026-03-09 | |
| PLNT | Planet Fitness, Inc. | Consumer Cyclical | Leisure | $5.2B | Morgan Stanley Reiterates Overweight Rating on Planet Fitness (PLNT) amid CFO transition | $117.00 | $76.29 | +52.2% | $132.43 | +72.3% | -15.0% | 2026-03-10 | |
| SEPN | Septerna, Inc. | Healthcare | Biotechnology | $1.1B | Cantor Fitzgerald Reiterates Overweight Rating on Septerna Inc (SEPN) | $60.00 | $28.02 | +113.8% | $39.00 | +39.0% | -14.0% | 2026-03-10 | |
| CGEM | Cullinan Therapeutics, Inc. | Healthcare | Medical - Pharmaceuticals | $774.1M | Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Stifel | $28.00 | $14.91 | +85.4% | $30.43 | +101.4% | -15.3% | 2026-03-10 | |
| DDD | 3D Systems Corporation | Technology | Computer Hardware | $322.8M | 3D Systems (DDD) PT Raised to $5 at Cantor Fitzgerald Following 'Respectable' Q4 Results | $5.00 | $2.45 | +98.4% | $5.00 | +98.4% | -12.3% | 2026-03-10 | |
| TEM | Tempus AI, Inc. | Healthcare | Medical - Healthcare Information Services | $9.0B | Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright | $95.00 | $50.90 | +82.6% | $87.11 | +67.4% | -1.0% | 2026-03-10 | |
| ORCL | Oracle Corporation | Technology | Software - Infrastructure | $480.0B | Deutsche Bank Reiterates Buy Rating on Oracle (ORCL) following Q3 results: "plenty to like in this print" | $300.00 | $163.09 | +84.8% | $280.79 | +73.0% | +2.8% | 2026-03-11 | |
| IRD | Opus Genetics, Inc. | Healthcare | Biotechnology | $353.6M | Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside opportunity" | $9.00 | $5.01 | +80.4% | $7.67 | +53.7% | -0.8% | 2026-03-11 | |
| JOBY | Joby Aviation, Inc. | Industrials | Airlines, Airports & Air Services | $8.9B | H.C. Wainwright Reiterates Buy Rating on Joby Aviation Inc (JOBY) | $18.00 | $9.74 | +76.0% | $15.75 | +54.0% | -11.3% | 2026-03-12 | |
| RWAY | Runway Growth Finance Corp. | Financial Services | Financial - Credit Services | $236.1M | Clear Street Reiterates Hold Rating on Runway Grouwth Finance Corp. (RWAY): 'We expect near-term portfolio churn' | $10.00 | $6.63 | +50.8% | $10.83 | +63.3% | -1.4% | 2026-03-13 | |
| NKTR | Nektar Therapeutics | Healthcare | Biotechnology | $1.7B | Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer | $140.00 | $73.25 | +91.1% | $136.40 | +86.2% | +14.5% | 2026-03-13 | |
| FNKO | Funko, Inc. | Consumer Cyclical | Leisure | $244.2M | Funko (FNKO) PT Raised to $6.50 at Texas Capital Securities | $6.50 | $4.13 | +56.2% | $6.50 | +56.3% | +5.9% | 2026-03-13 | |
| SVRA | Savara Inc. | Healthcare | Biotechnology | $1.0B | H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA date' | $10.00 | $5.23 | +93.4% | $10.25 | +98.2% | -2.4% | 2026-03-16 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | Jefferies Reiterates Buy Rating on Forgent Power Solutions (FPS): 'encouraged' by performance amid capacity ramp | $44.00 | $23.67 | +85.9% | $37.66 | +59.1% | 0.0% | 2026-03-16 | |
| ELDN | Eledon Pharmaceuticals, Inc. | Healthcare | Biotechnology | $209.8M | Leerink Partners Reiterates Outperform Rating on Eledon Pharamceuticals (ELDN) | $5.00 | $2.74 | +82.8% | $5.00 | +82.8% | +28.0% | 2026-03-16 | |
| HROW | Harrow Health, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.5B | BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations | $63.00 | $34.48 | +81.7% | $72.20 | +108.2% | +15.5% | 2026-03-18 | |
| NTLA | Intellia Therapeutics, Inc. | Healthcare | Biotechnology | $1.6B | Intellia Therapeutics price target raised to $35 from $29 at Leerink | $35.00 | $13.67 | +164.8% | $19.40 | +46.8% | +1.2% | 2026-04-27 | |
| OKLO | Oklo Inc. | Utilities | Regulated Electric | $12.1B | Oklo initiated with a Buy at Tigress Financial | $130.00 | $70.32 | +78.0% | $114.50 | +56.7% | -4.3% | 2026-04-27 | |
| QNC | Quantum eMotion Corp. | Technology | Semiconductors | $595.7M | Quantum eMotion initiated with a Buy at Alliance Global | $5.00 | $2.75 | +85.9% | $5.00 | +85.9% | +1.3% | 2026-04-27 | |
| KPTI | Karyopharm Therapeutics Inc. | Healthcare | Biotechnology | $73.7M | Karyopharm price target raised to $16 from $8 at Piper Sandler | $16.00 | $8.64 | +84.8% | $18.75 | +116.5% | -0.3% | 2026-04-27 | |
| JBIO | Jade Biosciences, Inc. | Healthcare | Biotechnology | $875.5M | Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright | $45.00 | $26.97 | +80.1% | $42.50 | +70.1% | +7.4% | 2026-04-27 | |
| HPP | Hudson Pacific Properties, Inc. | Real Estate | REIT - Office | $535.9M | N/A | $26.00 | $11.07 | +140.1% | $11.92 | +10.1% | -8.8% | +046027-01 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | CAE Inc. (CAE:CN) (CAE) PT Raised to Cdn$46 at RBC Capital | $46.00 | $23.67 | +94.3% | $35.19 | +48.7% | 0.0% | 2026-01-12 | |
| VSNT | Versant Media Group, Inc. Class A | Industrials | Advertising Agencies | $5.7B | Versant initiated with an Outperform at Wolfe Research | $52.00 | $34.11 | +53.4% | $52.00 | +53.3% | +16.3% | 2026-01-13 | |
| MBX | MBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | $1.0B | MBX Biosciences Inc (MBX) PT Raised to $88 at Guggenheim | $88.00 | $40.53 | +115.1% | $50.80 | +24.2% | -26.0% | 2026-01-16 | |
| AU | AngloGold Ashanti Plc | Basic Materials | Gold | $47.0B | Citi Upgrades Endeavour Group Ltd (EDV:AU) to Buy | $200.00 | $99.03 | +102.9% | $106.40 | +8.0% | -5.7% | 2026-01-16 | |
| NTLA | Intellia Therapeutics, Inc. | Healthcare | Biotechnology | $1.6B | Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright | $25.00 | $13.82 | +79.3% | $19.00 | +36.2% | -4.1% | 2026-01-28 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.4M | Korro Bio upgraded to Buy from Neutral at H.C. Wainwright | $20.00 | $13.31 | +71.1% | $19.67 | +68.3% | +8.6% | 2026-01-29 | |
| RAPP | Rapport Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $1.2B | Rapport Therapeutics initiated with an Overweight at Wells Fargo | $43.00 | $27.75 | +61.6% | $42.33 | +59.1% | +26.0% | 2026-02-02 | |
| HOOD | Robinhood Markets, Inc. | Financial Services | Financial - Capital Markets | $73.9B | Robinhood upgraded to Outperform from Peer Perform at Wolfe Research | $125.00 | $86.56 | +50.9% | $143.69 | +73.5% | -0.8% | 2026-02-09 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.4M | Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy | $18.00 | $11.24 | +60.2% | $19.43 | +72.9% | +13.0% | 2026-02-18 | |
| FOSL | Fossil Group, Inc. | Consumer Cyclical | Luxury Goods | $265.9M | Fossil initiated with an Outperform at Northland | $7.00 | $4.32 | +74.1% | $7.00 | +74.1% | +13.4% | 2026-02-19 | |
| MRVL | Marvell Technology, Inc. | Technology | Semiconductors | $133.0B | Marvell price target raised to $120 from $115 at UBS | $120.00 | $77.79 | +55.9% | $117.68 | +52.9% | +97.7% | 2026-02-23 | |
| PICS | PicS N.V. | Technology | Software - Infrastructure | $1.5B | BofA Securities Starts PicPay (PICS) at Buy | $27.00 | $17.76 | +67.2% | $24.50 | +51.7% | -27.7% | 2026-02-24 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $5.1T | Baird Reiterates Outperform Rating on NVIDIA (NVDA) following Coherent investment | $300.00 | $182.48 | +64.8% | $276.63 | +52.0% | +15.8% | 2026-03-02 | |
| SRPT | Sarepta Therapeutics, Inc. | Healthcare | Biotechnology | $2.2B | Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story" | $30.00 | $15.87 | +87.8% | $22.89 | +43.3% | +31.7% | 2026-03-03 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $5.1T | NVIDIA (NVDA) PT Raised to $300 at Wedbush | $300.00 | $180.05 | +66.9% | $277.46 | +54.4% | +17.3% | 2026-03-03 | |
| CMPX | Compass Therapeutics, Inc. | Healthcare | Biotechnology | $257.9M | Compass Therapeutics (CMPX) PT Raised to $9 at Jefferies | $9.00 | $5.53 | +62.8% | $11.00 | +98.9% | -66.3% | 2026-03-05 | |
| HOOD | Robinhood Markets, Inc. | Financial Services | Financial - Capital Markets | $73.9B | BofA Securities Reiterates Buy Rating on Robinhood Markets (HOOD) following Take Flight event | $122.00 | $80.56 | +52.9% | $132.13 | +65.6% | +2.9% | 2026-03-05 | |
| HEI-A | HEICO Corporation | Industrials | Aerospace & Defense | $28.5B | Jefferies Reiterates Buy Rating on HEICO (HEI) following 10-Q | $400.00 | $234.76 | +70.7% | $387.50 | +65.4% | -12.7% | 2026-03-05 | |
| MRVL | Marvell Technology, Inc. | Technology | Semiconductors | $133.0B | Marvell (MRVL) PT Raised to $164 at Craig-Hallum | $164.00 | $89.57 | +79.5% | $120.68 | +32.1% | +66.5% | 2026-03-06 | |
| JBI | Janus International Group, Inc. | Industrials | Construction | $756.1M | Benchmark Reiterates Buy Rating on Janus Int'l Group, Inc. (JBI), Estimates Unchanged | $9.00 | $5.29 | +65.1% | $9.00 | +65.1% | -0.1% | 2026-03-06 | |
| ADEA | Adeia Inc. | Technology | Software - Application | $3.4B | Adeia (ADEA) PT Raised to $40 at Rosenblatt following AMD agreement | $40.00 | $22.31 | +84.4% | $30.00 | +38.3% | +39.6% | 2026-03-09 | |
| RDNW | RideNow Group, Inc. | Consumer Cyclical | Auto - Dealerships | $142.3M | DA Davidson Reiterates Neutral Rating on RideNow Group (RDNW) as Momentum Continues | $6.00 | $3.71 | +61.7% | $6.00 | +61.7% | 0.0% | 2026-03-10 | |
| ONDS | Ondas Holdings Inc. | Technology | Communication Equipment | $5.1B | H.C. Wainwright Reiterates Buy Rating on Ondas Holdings Inc. (ONDS) | $17.00 | $10.01 | +71.0% | $15.63 | +57.2% | +6.4% | 2026-03-10 | |
| TDOC | Teladoc Health, Inc. | Healthcare | Medical - Healthcare Information Services | $1.1B | Deutsche Bank Upgrades Teladoc (TDOC) to Buy | $11.00 | $5.57 | +97.3% | $7.90 | +41.7% | +7.9% | 2026-03-10 | |
| SRPT | Sarepta Therapeutics, Inc. | Healthcare | Biotechnology | $2.2B | Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho | $31.00 | $17.04 | +81.9% | $24.50 | +43.8% | +23.5% | 2026-03-12 | |
| LTH | Life Time Group Holdings, Inc. | Consumer Cyclical | Leisure | $5.8B | UBS Reiterates Buy Rating on Life Time Group Holdings Inc (LTH) | $43.00 | $25.74 | +64.2% | $41.33 | +57.8% | +0.4% | 2026-03-12 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $5.1T | Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA) Ahead of GTC Event | $300.00 | $183.14 | +62.7% | $278.59 | +51.1% | +14.3% | 2026-03-12 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | Healthcare | Biotechnology | $5.8B | Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo | $143.00 | $91.15 | +58.9% | $140.18 | +55.7% | -5.6% | 2026-03-12 | |
| RLMD | Relmada Therapeutics, Inc. | Healthcare | Biotechnology | $520.0M | Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' | $10.00 | $5.91 | +69.2% | $9.00 | +52.3% | +20.0% | 2026-03-13 | |
| CIGI | Colliers International Group Inc. | Real Estate | Real Estate - Services | $5.5B | Stifel Reiterates Buy Rating on Colliers International (CIGI) amid Savills acquisition of Eastdil | $175.00 | $107.97 | +62.1% | $182.60 | +69.1% | +2.2% | 2026-03-13 | |
| ORKA | Oruka Therapeutics, Inc. | Healthcare | Biotechnology | $2.8B | BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Through Positively to ORKA-001/2' | $73.00 | $40.00 | +92.0% | $55.86 | +47.0% | +98.1% | 2026-03-13 | |
| CAPR | Capricor Therapeutics, Inc. | Healthcare | Biotechnology | $1.6B | Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result | $62.00 | $30.50 | +85.5% | $47.75 | +42.9% | +2.4% | 2026-03-13 | |
| RBRK | Rubrik, Inc. | Technology | Software - Infrastructure | $11.0B | Rubrik (RBRK) Reiterated at Overweight by Cantor Fitzgerald After Q4 Results | $85.00 | $53.43 | +57.4% | $92.17 | +70.6% | +1.0% | 2026-03-13 | |
| OMCL | Omnicell, Inc. | Healthcare | Medical - Healthcare Information Services | $2.1B | Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet | $60.00 | $34.40 | +70.9% | $55.25 | +57.4% | +30.1% | 2026-03-13 | |
| ELTX | Elicio Therapeutics, Inc. | Healthcare | Biotechnology | $201.3M | Elicio Therapeutics (ELTX) PT Raised to $17 at H.C. Wainwright | $17.00 | $12.20 | +56.0% | $17.00 | +56.0% | +0.4% | 2026-03-13 | |
| COF | Capital One Financial Corporation | Financial Services | Financial - Credit Services | $119.4B | Jefferies Reiterates Buy Rating on Capital One Financial (COF) after Feb credit metrics | $300.00 | $180.77 | +65.9% | $275.50 | +52.3% | +6.6% | 2026-03-16 | |
| WULF | TeraWulf Inc. | Financial Services | Financial - Capital Markets | $8.1B | TeraWulf price target raised to $41.50 from $37 at Morgan Stanley | $41.50 | $20.66 | +99.5% | $26.47 | +27.2% | -2.0% | 2026-04-27 | |
| PRLD | Prelude Therapeutics Incorporated | Healthcare | Biotechnology | $235.7M | Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright | $8.00 | $4.39 | +70.2% | $8.00 | +70.2% | -10.0% | 2026-04-27 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | BCE Inc. (BCE:CN) (BCE) PT Raised to Cdn$38 at RBC Capital | $38.00 | $23.67 | +60.5% | $33.86 | +43.1% | 0.0% | 2026-01-13 | |
| SSRM | SSR Mining Inc. | Basic Materials | Gold | $5.9B | SSR Mining price target raised to $38.50 from $34.50 at UBS | $38.50 | $22.83 | +56.1% | $33.50 | +35.8% | +17.6% | 2026-01-30 | |
| CIGI | Colliers International Group Inc. | Real Estate | Real Estate - Services | $5.5B | Colliers International upgraded to Strong Buy from Outperform at Raymond James | $200.00 | $134.62 | +55.8% | $188.00 | +46.5% | -14.0% | 2026-02-04 | |
| CPRI | Capri Holdings Limited | Consumer Cyclical | Luxury Goods | $2.4B | Capri Holdings price target raised to $32 from $31 at Barclays | $32.00 | $20.75 | +59.4% | $25.73 | +28.1% | +0.2% | 2026-02-04 | |
| XENE | Xenon Pharmaceuticals Inc. | Healthcare | Biotechnology | $4.2B | Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel | $66.00 | $42.63 | +55.5% | $55.75 | +31.4% | +26.4% | 2026-02-10 | |
| AERO | Grupo Aeroméxico, S.A.B. de C.V. | Industrials | Airlines, Airports & Air Services | $2.2B | Grupo Aeromexico price target raised to $28 from $27 at Barclays | $28.00 | $19.05 | +47.2% | $30.67 | +61.3% | -21.7% | 2026-02-10 | |
| NBIS | Nebius Group N.V. | Communication Services | Internet Content & Information | $32.2B | Nebius initiated with a Buy at Compass Point | $150.00 | $101.80 | +53.8% | $141.20 | +44.8% | +37.5% | 2026-02-18 | |
| ANET | Arista Networks, Inc. | Technology | Computer Hardware | $204.7B | Evercore ISI Reiterates Outperform Rating on Arista Networks (ANET) | $200.00 | $129.50 | +57.0% | $183.00 | +43.6% | +27.6% | 2026-02-24 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.3B | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord | $104.00 | $61.11 | +72.6% | $82.00 | +36.1% | -11.0% | 2026-02-26 | |
| CRM | Salesforce, Inc. | Technology | Software - Application | $173.9B | Goldman Sachs Reiterates Buy Rating on salesforce.com (CRM) | $281.00 | $199.47 | +46.5% | $299.00 | +55.9% | -4.5% | 2026-02-26 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.3B | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets | $105.00 | $59.74 | +73.7% | $85.43 | +41.3% | -11.3% | 2026-03-02 | |
| EEFT | Euronet Worldwide, Inc. | Technology | Software - Infrastructure | $3.0B | DA Davidson Reiterates Buy Rating on Euronet Worldwide (EEFT) | $112.00 | $74.22 | +50.5% | $103.00 | +38.4% | +2.1% | 2026-03-05 | |
| OKTA | Okta, Inc. | Technology | Software - Infrastructure | $13.0B | Okta, Inc (OKTA) PT Raised to $134 at Bernstein SocGen Group | $134.00 | $80.72 | +65.1% | $108.24 | +33.4% | -5.2% | 2026-03-06 | |
| XENE | Xenon Pharmaceuticals Inc. | Healthcare | Biotechnology | $4.2B | Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies | $100.00 | $62.76 | +59.3% | $76.67 | +22.2% | -14.6% | 2026-03-09 | |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | Biotechnology | $3.2B | Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer | $145.00 | $79.23 | +79.3% | $101.00 | +24.9% | +4.5% | 2026-03-09 | |
| RAPP | Rapport Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $1.2B | BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no readthrough" | $47.00 | $30.54 | +56.9% | $43.50 | +45.2% | +11.9% | 2026-03-09 | |
| ALMS | Alumis Inc. Common Stock | Healthcare | Biotechnology | $2.9B | Raymond James Starts Alumis Inc (ALMS) at Strong Buy | $46.00 | $28.10 | +63.7% | $38.44 | +36.8% | -15.7% | 2026-03-10 | |
| SGRY | Surgery Partners, Inc. | Healthcare | Medical - Care Facilities | $1.9B | UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders | $21.00 | $13.48 | +55.6% | $18.85 | +39.7% | +6.7% | 2026-03-11 | |
| AVAH | Aveanna Healthcare Holdings Inc. | Healthcare | Medical - Care Facilities | $1.4B | Truist Securities Reiterates Hold Rating on Aveanna Healthcare Holdings Inc (AVAH) amid acquisition | $10.00 | $7.00 | +42.9% | $11.25 | +60.7% | -5.3% | 2026-03-12 | |
| DT | Dynatrace, Inc. | Technology | Software - Application | $11.0B | BofA Securities Reiterates Buy Rating on Dynatrace Inc. (DT): "risk/reward is very attractive" | $64.00 | $38.02 | +66.7% | $51.47 | +34.1% | -5.2% | 2026-03-12 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.3B | Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign" | $103.00 | $59.07 | +72.1% | $86.60 | +44.7% | -10.4% | 2026-03-12 | |
| NBIS | Nebius Group N.V. | Communication Services | Internet Content & Information | $32.2B | Nebius Group (NBIS) PT Raised to $200 at DA Davidson | $200.00 | $129.85 | +53.2% | $176.60 | +35.3% | +2.7% | 2026-03-16 | |
| GDOT | Green Dot Corporation | Financial Services | Financial - Credit Services | $676.5M | Craig-Hallum stays Buy on Green Dot (GDOT): 'opportunity' as current stock indicates 0.68x TBV multiple | $18.00 | $11.32 | +56.2% | $16.13 | +40.0% | +5.7% | 2026-03-17 | |
| CELH | Celsius Holdings, Inc. | Consumer Defensive | Beverages - Non-Alcoholic | $8.5B | Morgan Stanley stays Overweight on Celsius Holdings (CELH), estimates Alani growth in mid-80%s | $64.00 | $43.96 | +45.8% | $67.25 | +53.2% | -24.9% | 2026-03-17 | |
| GDS | GDS Holdings Limited | Technology | Information Technology Services | $8.1B | GDS Holdings (GDS) PT Raised to $67.50 at Macquarie as Chinese hyperscalers step up CapEx commitments | $67.50 | $44.49 | +50.8% | $62.17 | +38.9% | -7.2% | 2026-03-18 | |
| GSHD | Goosehead Insurance, Inc | Financial Services | Insurance - Diversified | $1.8B | Goosehead Insurance price target raised to $85 from $81 at UBS | $85.00 | $48.70 | +70.2% | $67.14 | +34.4% | -1.9% | 2026-04-27 | |
| QXO | QXO, Inc. | Industrials | Industrial - Distribution | $14.3B | QXO price target raised to $32 from $30 at Oppenheimer | $32.00 | $19.62 | +52.6% | $30.20 | +44.0% | -6.1% | 2026-04-27 | |
| SAP | SAP SE | Technology | Software - Application | $202.8B | SAP price target raised to $257 from $256 at Barclays | $257.00 | $173.89 | +46.7% | $391.67 | +123.5% | -0.7% | 2026-04-27 | |
| HMH | HMH Holding Inc. Class A Common Stock | Energy | Oil & Gas Equipment & Services | $882.4M | HMH Holding initiated with an Overweight at Piper Sandler | $32.00 | $20.36 | +59.0% | $28.67 | +42.4% | +1.7% | 2026-04-27 |